For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240422:nRSV5653La&default-theme=true
RNS Number : 5653L Renalytix PLC 22 April 2024
Renalytix plc
("Renalytix" or the "Company")
Result of General Meeting
LONDON and SALT LAKE CITY, 22 April 2024 - Renalytix plc
(https://renalytix.com/) (NASDAQ: RNLX) (LSE: RENX) announces that at the
General Meeting ("GM") held earlier today all resolutions were passed. Further
details of each of the resolutions are set out in Proxy Statement that
contains the Notice of General Meeting, which was sent to shareholders on 3
April 2024.
The results of the GM are detailed below:
Resolution Votes in favour % Votes against % Votes withheld
Resolution 1 50,091,780 98.77% 621,329 1.23% 120,431
Resolution 2 45,880,130 90.47% 4,832,979 9.53% 120,431
Resolution 3 50,072,092 98.74% 641,404 1.26% 120,044
Resolution 4 45,853,622 90.42% 4,859,914 9.58% 120,004
For further information, please contact:
Renalytix plc www.renalytix.com (http://www.renalytix.com)
James McCullough, CEO Via Walbrook PR
Stifel (Nominated Adviser to the Company) Tel: 02077107600
Nicholas Moore / Alex Price / Nick Harland / Samira Essebiya / Harry Billen
Investec Bank plc Tel: 020 7597 4000
Gary Clarence / Shalin Bhamra
Walbrook PR Limited Tel: 020 7933 8780 or renalytix@walbrookpr.com
(mailto:renalytix@walbrookpr.com)
Paul McManus / Alice Woodings / Charlotte Edgar
Mob: 07980 541 893 / 07407 804 654 / 07884 664 686
CapComm Partners Tel: 415-389-6400 or investors@renalytix.com (mailto:investors@renalytix.com)
Peter DeNardo
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory
services company that is the global founder and leader in the new field of
bioprognosis™ for kidney health. The leadership team, with a combined 200+
years of healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment for rapid
progressive decline in kidney function in adult patients with T2D and early
CKD (stages 1-3). We believe that by understanding how disease will progress,
patients and providers can take action early to improve outcomes and reduce
overall health system costs. For more information, visit www.renalytix.com
(http://www.renalytix.com/) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END ROMPPUQUCUPCGAP